Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.30 |
| ▸ | ACP1 | P24666 | 2/20 | 0.30 |
| ▸ | CDC25B | P30305 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224832 | 0.81 | TDP1 (0.41) | BACE1KDM4EALDH1A1MAPTGLA | |
| SCHEMBL29663487 | 0.80 | BACE1 (0.40) | BACE1KDM4EALDH1A1POLBMAPT | |
| SCHEMBL20826897 | 0.78 | KDM4E (0.50) | BACE1KDM4EALDH1A1POLBMAPT | |
| SCHEMBL7995598 | 0.78 | HSD17B10 (0.52) | BACE1KDM4EALDH1A1POLBMAPT | |
| SCHEMBL9533484 | 0.75 | TSHR (0.43) | BACE1KDM4EALDH1A1POLBMAPT | |
| SCHEMBL31603 | 0.75 | BACE1 (0.44) | BACE1KDM4EALDH1A1POLBMAPT | |
| SCHEMBL28927137 | 0.75 | LMNA (0.54) | BACE1KDM4EALDH1A1POLBMAPT | |
| SCHEMBL28697084 | 0.75 | BACE1 (0.49) | BACE1GLANPSR1 | |
| SCHEMBL23458430 | 0.74 | BACE1 (0.39) | BACE1KDM4EALDH1A1POLBMAPT | |
| SCHEMBL22975210 | 0.74 | GLA (0.35) | BACE1GLANPSR1PTPN1ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2945623-B1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2018-09-05 | — | — | EP | disclosed |
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
| EP-2945623-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou yunxuan yiyaokeji youxiangongsi (Su Zhou Yuan Pharm) (CN) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014113191-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | ZHANG XIAOHU (CN) | 2014-07-24 | — | — | WO | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| EP-2526945-A1 | New CRTH2 Antagonists | Almirall, S.A. (ES) | 2012-11-28 | — | — | EP | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| EP-2380890-A1 | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2011-10-26 | — | — | EP | disclosed |
| US-20110253549-A1 | WASHING APPARATUS AND METHOD OF DEODORIZING WASHING WATER | KANNO MINORU | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | BACE1 219/4885KDM4E 2794/4885ALDH1A1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.